Search results
Carisma is led by a seasoned management team with extensive cell therapy, oncology and drug development experience, as well as an unrelenting focus on patients. Everything we do is centered around igniting hope in patients living with cancer and other serious conditions.
5 days ago · PHILADELPHIA, July 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing ...
Dec 14, 2023 · The highlighted data demonstrated that Carisma's CAR-M therapy can be directly produced in vivo, or within the body, and can successfully redirect endogenous myeloid cells against...
May 8, 2024 · The data showed that a single dose of macrophages expressing a dominant negative TGFβ receptor, which nullified pro-fibrotic TGFβ signaling in the lung, prevented fibrosis in a bleomycin mouse model of pulmonary fibrosis, with a 90% reduction in fibrosis relative to untreated control.
Dec 14, 2023 · First lead candidate to address a solid tumor indication with significant unmet medical need. Supportive pre-clinical proof of concept data reported at SITC 2023 that demonstrated feasibility, tolerability and early efficacy of in vivo CAR-M therapy utilizing mRNA/LNPs in solid tumors.
Jun 27, 2024 · Nomination triggers a $2 million milestone payment to Carisma. PHILADELPHIA, June 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage ...
People also ask
Who is Carisma Therapeutics?
What does Carisma do?
Is Carisma obligated to update the forward-looking statements?
Where can I find more information about carismatx?
Nov 12, 2021 · PHILADELPHIA, Nov. 12, 2021 /PRNewswire/ -- Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, presented today...
